Posted by admin on May 14th, 2022

Abiomed (NASDAQ:ABMD – Get Rating) and TELA Bio (NASDAQ:TELA – Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability.

Abiomed has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, TELA Bio has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500.

This table compares Abiomed and TELA Bio’s net margins, return on equity and return on assets.

This table compares Abiomed and TELA Bio’s revenue, earnings per share and valuation.

Abiomed has higher revenue and earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.

92.0% of Abiomed shares are owned by institutional investors. 3.0% of Abiomed shares are owned by insiders. Comparatively, 15.9% of TELA Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

This is a breakdown of current ratings and recommmendations for Abiomed and TELA Bio, as provided by MarketBeat.com.

Abiomed presently has a consensus price target of $335.00, suggesting a potential upside of 31.81%. TELA Bio has a consensus price target of $22.00, suggesting a potential upside of 159.43%. Given TELA Bio’s stronger consensus rating and higher probable upside, analysts plainly believe TELA Bio is more favorable than Abiomed.

Abiomed beats TELA Bio on 9 of the 13 factors compared between the two stocks.

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

About TELA Bio (Get Rating)

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Receive News & Ratings for Abiomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed and related companies with MarketBeat.com's FREE daily email newsletter.

Raymond James Boosts Sierra Wireless (TSE:SW) Price Target to C$20.00

Zacks: Brokerages Anticipate Alithya Group Inc. (NASDAQ:ALYA) Will Announce Quarterly Sales of $77.62 Million